Illumina, Inc. Announces Favorable Patent Claim Construction Ruling in Litigation Against Complete Genomics, Inc.

Published: Feb 16, 2012

SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (NASDAQ: ILMN - News) announced today that Magistrate Judge Elizabeth D. Laporte of the U.S. District Court for the Northern District of California issued a Claim Construction Order in the litigation brought by Illumina against Complete Genomics, Inc. Illumina has accused Complete Genomics of infringing U.S. Patent No. 6,306,597.

Judge Laporte’s February 8 Order provides the Court’s interpretation of the disputed terms in the patent asserted by Illumina. In its Order, the Court adopted constructions favorable to Illumina for the key terms in dispute. Illumina believes that the Court’s interpretations affirm the breadth of the patent and Illumina’s position that Complete Genomics infringes the patent.

“We are very pleased with the Court’s Claim Construction Order and look forward to proceeding with the remainder of the case,” said Jay Flatley, Illumina’s President and CEO. Illumina is seeking remedies including lost profits, a reasonable royalty and a permanent injunction.

About Illumina

Illumina ( is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release contains forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.


Illumina, Inc.


Kevin Williams, MD

Investor Relations




Laura Trotter

Public Relations


Back to news